R&D Systems™ Recombinant Human IL-39 Fc Chimera Protein

Description

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity

The Recombinant Human IL-39 Fc Chimera Protein is derived from HEK293. The Recombinant Human IL-39 Fc Chimera Protein has been validated for the following applications: Bioactivity.

Specifications

• Accession Number: Q14213, Q9NPF7
• For Use With (Application): Bioactivity
• Molecular Weight (g/mol): 69 kDa
• Quantity: 50 μg
• Source: Human embryonic kidney cell,HEK293-derived human IL-39 (IL-23p19/EBI3) protein Human EBI3 (Arg21-Lys229,Gln95Cys) Accession &Num; Q14213 GGGSGGGSGGGS Human IL-23p19 (Arg20-Pro189) Accession &Num; Q9NPF7 IEGRMD Human IgG1 (Pro100-Lys330)
• Storage Requirements: 12 months from date of receipt, <= -20 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, <= -20 °C under sterile conditions after reconstitution.
• Regulatory Status: RUO
• Endotoxin Concentration: <0.10 EU per 1 μg of the protein by the LAL method.
• Specific Reactivity: IL-39 (IL-23p19/EBI3)
• Conjugate: Unconjugated
• Species: Human
• Recombinant: Recombinant
• Reconstitution: Reconstitute at 200 μg/mL in PBS.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity or Quality Grade: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.